Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients with Advanced Malignancies

Principal Investigator: Krishnamurthy, Anuradha

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

S2303 Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Principal Investigator: Mukherjee, Sarbajit

(APEC1621F) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF ENSARTINIB IN PATIENTS WITH TUMORS HARBORING ALK OR ROS1 GENOMIC ALTERATIONS

Principal Investigator: Twist, Clare J

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

(ANBL2131) A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Principal Investigator: Twist, Clare J

A single-arm, open-label, Dose Escalation + Cohort Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 given orally to Patients with Refractory or Relapsed Chronic Myelogenous Leukemia

Principal Investigator: Thompson, J

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A phase 2 trial of chemotherapy, Pembrolizumab and Propranolol in advanced esophageal/gastroesophageal junction adenocarcinoma patients.

Principal Investigator: Mukherjee, Sarbajit

(AALL2121) A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Principal Investigator: Mallhi, Kanwal

NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL
TRIAL EVALUATION (GUIDANCE)

Principal Investigator: Kuettel, Michael R

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRa antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or…

Principal Investigator: Zsiros, Emese

An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 1b Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity

Principal Investigator: Chatta, Gurkamal S

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Principal Investigator: Cortese, Matthew J

A Phase 3, Open-label, Randomized, Non-Inferiority Trial of Subcutaneous (SC) versus Intravenous (IV) Nivolumab in Advanced, or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy

Principal Investigator: George, Saby

A Phase 2 Study of Iadademstat in Combination with Paclitaxel in Relapsed or Refractory Small Cell Lung Cancer and Extrapulmonary High Grade Neuroendocrine Carcinomas ( GI-203)

Principal Investigator: Iyer, Renuka V

(ACNS1821) A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Principal Investigator: Twist, Clare J

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

Principal Investigator: Dy, Grace K

A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers

Principal Investigator: Fountzilas, Christos

Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy (D933GC00002)

Principal Investigator: Iyer, Renuka V

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Switzer, Benjamin J

Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients with Loco-regionally Advanced or Recurrent Colorectal Cancer Undergoing Surgery ; Phase I/II

Principal Investigator: Dakwar, Anthony

Phase III Randomized Trial of Stereotactic ablative radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)

Principal Investigator: Prasad, Dheerendra

Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

Principal Investigator: Hillengass, Jens